B
Bullisch
Bullisch · 25%DBVT
$5.31
Szenariopreis
$9.050
-0.060 (-0.66%)Zum Schluss
Loading chart…
- Hoch
- 9.130
- Eröffnung
- 9.020
- Volumengewichteter Durchschnittskurs
- 8.94
- Volumen
- 592.92K
- Marktkap.
- 81.60M
- Tief
- 8.630
- Umsatz
- 5.30M
- EV/EBITDA, TTM
- -0.09
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. It dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The Company's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The Company operates one subsidiary DBV Technologies Inc. in the United States.
KI-Analyse of Dbv Technologies SA (DBVT)
HaltenDBV Technologies is currently not a strong buy due to its low price of $9.05 and a very low RSI of 24.871, indicating oversold conditions. However, the company has a strong gross margin of 100% and significant cash reserves of $174.9 million, which provide some stability. The main risk is its negative net income, which reached -$50.4 million in Q2 2026, indicating ongoing financial challenges.
Analystenbewertungen (9)
+412.71% Aufwärtspotenzial
Kaufen
8 Kaufen
1 Halten
0 Verkaufen
Aktuell: 9.05
Tief
40.00
Durchschnitt
46.40
Hoch
51.00
H.C. Wainwright
Kaufen
$40
2026-06-30
H.C. Wainwright
2026-06-30
Kursziel
$40
Kaufen
Cantor Fitzgerald
Übergewichten
$48
2026-06-30
Cantor Fitzgerald
2026-06-30
Kursziel
$48
Übergewichten
Citizens
Überdurchschnittlich
$55
2026-06-30
Citizens
2026-06-30
Kursziel
$55
Überdurchschnittlich
Citizens
Überdurchschnittlich
$55
2026-05-01
Citizens
2026-05-01
Kursziel
$55
Überdurchschnittlich
Goldman Sachs
Verkaufen
—
2026-04-09
Goldman Sachs
2026-04-09
Kursziel
—
Verkaufen
Bewertungskennzahlen
Das aktuelle erwartete KGV von Dbv Technologies SA (DBVT) beträgt 0.00, verglichen mit dem 5-Jahres-Durchschnitt von -3.76.
Alphio-AI-Kursszenarien für DBVT
Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.
Whales, die DBVT halten
Event-Zeitleiste
News
7.009-02NewsfilterCompany Voting Rights and Total Shares Information
2.009-02Yahoo FinanceDBV Technologies Voting Rights and Shares Information
8.507-30GlobenewswireDBV Technologies Sells $50 Million ADSs via ATM Program
- 8.507-17Newsfilter
DBV Technologies Files ATM Prospectus for Up to $150 Million
9.507-16seekingalphaDBV Technologies Q2 Earnings Beat Expectations
DBVT FAQ – beantwortet von Alphio AI
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. It dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The Company's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The Company operates one subsidiary DBV Technologies Inc. in the United States. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).
DBV Technologies is currently not a strong buy due to its low price of $9.05 and a very low RSI of 24.871, indicating oversold conditions. However, the company has a strong gross margin of 100% and significant cash reserves of $174.9 million, which provide some stability. The main risk is its negative net income, which reached -$50.4 million in Q2 2026, indicating ongoing financial challenges.
9 analysts cover DBVT: 8 rate it Buy, 1 Hold and 0 Sell. The average price target is 46.40.
Community
Mehr ↗Noch keine Beiträge
Registriere dich oder melde dich an, um mitzudiskutierenDiese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.